ASCO 2025 | CAR T-cell therapy management lessons inform TIL therapy toxicities and optimize post discharge care
James Smithy
• 2 Jun 2025
James Smithy, MD, MHS, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the importance of tailoring CAR T-cell therapy management to individual products and their unique toxicity profiles. Dr Smithy emphasizes the need for careful consideration of timing and severity of adverse events (AEs) for each product, and highlights the value of real-world assessment and trial data in guiding best practices for post-discharge care protocols. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
